3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Recurrence
1
Metastatic Neuroendocrine Prostate Cancer
1
Medulloblastoma
1
Ependymoma
1
Advanced Solid Tumors
1
Interventions
Injections
20
Carboplatin
9
pembrolizumab
8
Bevacizumab
6
Pemetrexed
5
Paclitaxel
5
Leucovorin
5
Fluorouracil
5
fludarabine
4
Oxaliplatin
4
Docetaxel
4
sotorasib
3
atezolizumab
3
Drug Therapy
3
Cyclophosphamide
3
Capecitabine
3
trifluridine tipiracil drug combination
2
trametinib
2
toripalimab
2
spartalizumab
2
palbociclib
2
olaparib
2
Panitumumab
2
Immune Checkpoint Inhibitors
2
Fulvestrant
2
Etoposide
2
Cisplatin
2
Cetuximab
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumors
×
Antiemetics
×
1 year
×
Clear all
NCT06242691
2026-06-05
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2
Completed
13 enrolled
21 charts